Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX66 + Radiotherapy in Late-Stage Prostate Cancer
NCT03307629Phase 1Completed
- Sponsor
- Noxopharm Limited
- Start
- Nov 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of idronoxil in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Noxopharm Limited. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events Including SAEs at Week 24, Assessment of Laboratory Results at Week 24 and 1 more. Started Nov 2017; status: completed.
02
Drugs
idronoxil
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03307629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307629.